Indications
Therapeutic Asset Ratings
9,920 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
LY3143921
Esophageal Squamous Cell Carcinoma
Cancer Research UK
P1
CC
(43)
LY3143921
Head And Neck Squamous Cell Carcinoma
Cancer Research UK
P1
CC
(43)
LY3143921
Urothelial Carcinoma
Cancer Research UK
P1
CC
(43)
LY3143921
Triple-Negative Breast Carcinoma
Cancer Research UK
P1
CC
(43)
LY3143921
Malignant Pancreatic Neoplasm
Cancer Research UK
P1
CC
(43)
LY 3200882
Neoplasm
Eli Lilly and Company
P1
CC
(43)
LY 3410738
Acute Myeloid Leukemia
Eli Lilly and Company
P1
CC
(43)
LY 3410738
Cancer
Eli Lilly and Company
P1
CC
(43)
LY 3410738
Cholangiocarcinoma
Eli Lilly and Company
P1
CC
(43)
LY 3410738
Chondrosarcoma
Eli Lilly and Company
P1
CC
(43)
LY 3410738
Chronic Myelomonocytic Leukemia
Eli Lilly and Company
P1
CC
(43)
LY 3410738
Glioma
Eli Lilly and Company
P1
CC
(43)
LY 3410738
Myelodysplastic Syndrome
Eli Lilly and Company
P1
CC
(43)
LY 3410738
Myeloproliferative Neoplasm
Eli Lilly and Company
P1
CC
(43)
ly3885125
Inherited Lipid Metabolism Disorder
Eli Lilly and Company
P1
CC
(43)
ly4050784
SMARCA4-Deficient Sarcoma Of Thorax
Eli Lilly and Company
P1
CC
(43)
ly4052031
Cancer
Eli Lilly and Company
P1
CC
(43)
ly4052031
Renal Pelvis Carcinoma
Eli Lilly and Company
P1
CC
(43)
ly4052031
Urinary Bladder Neoplasm
Eli Lilly and Company
P1
CC
(43)
ly4066434.
Cancer
Eli Lilly and Company
P1
CC
(43)
ly4066434.
Colorectal Cancer
Eli Lilly and Company
P1
CC
(43)
ly4066434.
Non-Small Cell Lung Carcinoma
Eli Lilly and Company
P1
CC
(43)
ly4066434.
Pancreatic Ductal Adenocarcinoma
Eli Lilly and Company
P1
CC
(43)
ly4101174
Cancer
Eli Lilly and Company
P1
CC
(43)
ly4101174
Renal Pelvis Carcinoma
Eli Lilly and Company
P1
CC
(43)
Showing 3201 to 3225 of 9,920 assets
Previous
Page 129 of 397
Next
